PPT Slide

MIRACL: Primary Endpoint

Relative risk = 0.84p=0.048

Atorvastatin

Placebo

0

5

10

15

0

4

8

12

16

Time since randomization (weeks)

Cumulative Incidence (%)

Time to first occurrence of:

• Death (any cause)

• Nonfatal MI

• Resuscitated cardiac arrest

• Worsening angina with new objective evidence requiring urgent rehospitalization

17.4%

14.8%

Previous slide

Next slide

Back to first slide

View graphic version